It has been declared that in the case of advanced NSCLC (PD‐L1 positive type), anti‐PD‐(L)1 antibodies outperform chemotherapy in terms of survival outcomes and safety, while having adverse effects and being life‐threatening [167]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.